Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Heart failure

The many faces of heart failure with preserved ejection fraction

Nature Reviews Cardiology volume 9, pages 555–556 (2012)Cite this article

Subjects

By definition, patients with heart failure and preserved ejection fraction are characterized by a normal or near-normal left ventricular ejection fraction, but marked heterogeneity in the extent of other cardiac structural and functional abnormalities exists. Improved appreciation of this diversity might provide insights into prognosis and therapeutic interventions.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Mechanisms of HFpEF.

References

  1. Patel, K. et al. Angiotensin receptor blockers and outcomes in real-world older patients with heart failure and preserved ejection fraction: a propensity-matched inception cohort clinical effectiveness study. Eur. J. Heart Fail. http://dx.doi.org/10.1093/eurjhf/hfs101.

  2. Dougherty, A. H., Naccarelli, G. V., Gray, E. L., Hicks, C. H. & Goldstein, R. A. Congestive heart failure with normal systolic function. Am. J. Cardiol. 54, 778–782 (1984).

    Article  CAS  Google Scholar 

  3. Lam, C. S. P., Donal, E., Kraigher-Krainer, E. & Vasan, R. S. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur. J. Heart Fail. 13, 18–28 (2011).

    Article  Google Scholar 

  4. Borlaug, B. A. & Paulus, W. J. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur. Heart J. 32, 670–679 (2011).

    Article  Google Scholar 

  5. McMurray, J. J. V. et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 33, 1787–1847 (2012).

    Article  Google Scholar 

  6. Solomon, S. D. et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 116, 1482–1487 (2007).

    Article  Google Scholar 

  7. Zile, M. R. et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation 124, 2491–2501 (2011).

    Article  Google Scholar 

  8. Lam, C. S. P. et al. Cardiac structure and ventricular–vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation 115, 1982–1990 (2007).

    Article  Google Scholar 

  9. Persson, H. et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence: results from the CHARM Echocardiographic Substudy—CHARMES. J. Am. Coll. Cardiol. 49, 687–694 (2007).

    Article  Google Scholar 

  10. Redfield, M. M. et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289, 194–202 (2003).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiovascular Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, 02445, MA, USA

    Amil M. Shah & Marc A. Pfeffer

Authors
  1. Amil M. Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marc A. Pfeffer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marc A. Pfeffer.

Ethics declarations

Competing interests

Amil S. Shah is or has been a consultant for Novartis Pharma. Marc A. Pfeffer receives honoraria and/or research grants, or serves as a consultant for Affectis, Amgen, Anthera, Baxter, Boston Scientific, Bristol–Myers Squibb, Celladon, Daiichi Sankyo, Eleven Biotherapeutics, GlaxoSmithKline, Hamilton Health Sciences, Novartis, Pfizer Japan, Roche, Sanofi–Aventis, Servier, and the University of Oxford. The Brigham and Women's Hospital has patents for the use of inhibitors of the renin–angiotensin system in selected survivors of myocardial infarction with Novartis Pharmaceuticals AG and Boehringer Ingelheim, GMBH. Marc A. Pfeffer is a coinventor. His share of the licensing agreements is irrevocably transferred to charity.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shah, A., Pfeffer, M. The many faces of heart failure with preserved ejection fraction. Nat Rev Cardiol 9, 555–556 (2012). https://doi.org/10.1038/nrcardio.2012.123

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2012.123

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing